orthocell.comCrawled Nov 14, 2026
Nerve repair surgery can restore sensation or movement, improving quality of life for those with nerve damage and chronic pain.
A dedicated educational repository designed to support surgeons and healthcare professionals with resources and information.
A paper instruction for use (IFU) is available upon request through distributors or the Orthocell website.
Orthocell’s CEO and Managing Director Paul Anderson has featured on Beyond The Medicine Cabinet podcast to talk about regenerative nerve repair, and how Orthocell’s Remplir collagen nerve wrap is revolutionising surgery for patients with peripheral nerve injuries.
This week, Orthocell’s CEO and MD, Paul Anderson, joined Tim Banfield on Euroz Hartley's Finding the Front Podcast.
Gregor Maier, VP Global Commercialisation and Professional Engagements, joined Orthocell in its early years and helped develop its cell therapy, dental, and nerve repair businesses. He now leads commercialisation and professional engagement activities globally, with a focus on the United States.
Mr Walker is a highly experienced sales executive, who has successfully led global product launches and sales strategies, most notably helping to lead the growth of nerve repair device sales at Axogen.
Orthocell Limited (ASX: OCC) has recorded its strongest month of U.S. sales for its nerve repair product, Remplir, since launch.
Orthocell CEO and Managing Director Paul Anderson presents at the Canaccord Genuity 46th Annual Growth Conference in Boston, engaging with global investors.
Orthocell's strategic partner, Marine Biomedical, has received U.S. FDA 510(k) clearance for PearlBone. PearlBone can now be marketed in the United States
Mr Leach is a highly regarded senior marketing executive with extensive knowledge and experience in the development and commercialization of technologies for peripheral nerve regeneration and repair in the USA.
Orthocell introduces Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, as part of its ‘Meet the Board’ video series.
The fourth episode of Orthocell's 'Meet the Board' video series is now live - featuring Independent Director, Dr. Ravi Thadhani.
Manufacturing and exporting novel regenerative medicine products worldwide. Biological medical devices & therapies for nerve, tendon, cartilage & dental bone.
Orthocell Ltd headquarters is located at Building 191, Murdoch University, South Street, Murdoch, WA 6150. Contact details for sales representatives and surgeons are available.
Proprietary SMRT manufacturing of Remplir collagen nerve wrap & Striate+ collagen membranes. Cell therapies OrthoACI for cartilage & OrthoATI for tendon injuries.
Effective 27 July, 2026
Orthocell Limited (ACN 118 897 135) (Company) gives notice pursuant to section 110K of the Corporations Act 2001 (Cth) (Corporations Act) of the rights of
Marine Biomedical, Orthocell’s strategic partner, secures U.S. FDA 510(k) clearance for PearlBone™. The product can now be marketed in the U.S. for its approved medical applications. Orthocell references the clearance in its ASX announcement.
Nov 2026OrthocellNews article
Orthocell Limited reports its highest U.S. sales month for **Remplir™**, its nerve repair product, since its market introduction. The company highlights sustained demand for the regenerative medicine solution in the American market. No specific sales figures or customer details are disclosed in the announcement.
Nov 2026OrthocellNews article
Orthocell held a quarterly investor webinar on October 22, featuring CEO Paul Anderson, CFO Jim Piper, and Chief Commercial Officer Adam Wood. The session covered the company’s recent performance and progress. Orthocell focuses on regenerative medicine solutions.
Oct 2026OrthocellNews article
Orthocell reports promising early clinical outcomes from its **Remplir™** nerve repair device, used in the first series of robotic prostate cancer surgeries. The device demonstrates positive results in restoring nerve function post-surgery, according to the company’s findings. This marks a potential advancement in preserving continence and erectile function for patients undergoing prostatectomy.
Oct 2026OrthocellNews article